A Phase 3 interventional study of COX-2 inhibitor in Primary Hypertrophic Osteoarthropathy, sponsored by Peking Union Medical College Hospital. Status unknown at 1 site in China. Open to participants aged 16 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-05-08.
Sponsored by Peking Union Medical College Hospital · Phase 3, Interventional, and Treatment
The purpose of this study is to determine whether COX-2 inhibitor is effective in the treatment of primary hypertrophic osteoarthropathy
Patients with primary hypertrophic osteoarthropathy(PHO) were diagnosed based on clinical manifestations and symptoms. PHO patients were treated with COX-2 inhibitor after signing informed consent. The extend of alleviation, the change of the markers on prostaglandin E metabolic pathway and the adverse event on different time points were recorded to identify the efficacy and safety.
656 studies on the registry are indexed under Hypertrophy; 87 are open to participants now.
This study's planned enrollment of 30 is below the median of 50 across 460 interventional studies indexed under Hypertrophy.
Browse Hypertrophy studies →Peking Union Medical College Hospital is the lead sponsor of 1,115 studies on the registry; 463 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients who take COX-2 inhibitor
Drug: COX-2 inhibitor
oral COX-2 inhibitor intake 60mg qd
Also known as: EtoriCoxib
Prostaglandin E2（PGE2） level change after COX-2 inhibitor treatment in PHO patients
measure the serum prostaglandin E2 level at 3 months
Time frame: 3 months
Prostaglandin E2（PGE2） level change after COX-2 inhibitor treatment in PHO
measure the serum prostaglandin E2 level at 6 months
Time frame: 6 months
change in pain on VAS scale after COX-2 inhibitor treatment
use Visual Analogue Score (VAS) to evaluate pain
Time frame: 3 months
change in pain on VAS scale after COX-2 inhibitor treatment
Time frame: 6 months
change in pain on VAS scale after COX-2 inhibitor treatment
Time frame: 12 months
The volume of distal part of middle finger change after COX-2 inhibitor treatment
Both left and right fingers were measured twice and the average value was defined as volume of distal part of middle finger
Time frame: 3 months
The volume of distal part of middle finger change after COX-2 inhibitor treatment
Both left and right fingers were measured twice and the average value was defined as volume of distal part of middle finger
Time frame: 6 months
The volume of distal part of middle finger change after COX-2 inhibitor treatment
Both left and right fingers were measured twice and the average value was defined as volume of distal part of middle finger
Time frame: 12 months
Circumference of knee joint change after COX-2 inhibitor treatment
During the circumference of knee joint (CKJ) assessment, the patient was standing straight and the knee was extended as much as possible. The tester stood closest to the examined leg and used a tape to measure the circumference just at the base of the patella. Both legs were measured twice and the average value was used as CKJ.
Time frame: 3 months
Circumference of knee joint change after COX-2 inhibitor treatment
During the circumference of knee joint (CKJ) assessment, the patient was standing straight and the knee was extended as much as possible. The tester stood closest to the examined leg and used a tape to measure the circumference just at the base of the patella. Both legs were measured twice and the average value was used as CKJ.
Time frame: 6 months
Circumference of knee joint change after COX-2 inhibitor treatment
During the circumference of knee joint (CKJ) assessment, the patient was standing straight and the knee was extended as much as possible. The tester stood closest to the examined leg and used a tape to measure the circumference just at the base of the patella. Both legs were measured twice and the average value was used as CKJ.
Time frame: 12 months
This study is status unknown, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking Union Medical College Hospital